-
King Pharmaceuticals, Inc et al v. EON Labs, Inc. DC CAFC
- 1:04-cv-05540
- E.D.N.Y.
- Judge: Roslynn R. Mauskopf +1
- Filed: 12/17/2004
- Closed: 03/11/2011
- Latest Docket Entry: 10/27/2011
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
1
Accused
Product
2
Patents-in-Suit
2,276
Days in
Litigation
-
King Pharmaceuticals, Inc et al v. EON Labs, Inc. DC CAFC
- 1:04-cv-05540
- E.D.N.Y.
- Judge: Roslynn R. Mauskopf +1
- Filed: 12/17/2004
- Closed: 03/11/2011
- Latest Docket Entry: 10/27/2011
- PACER
- Docket updated daily
Cause of Action
Willful Patent Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of using metaxalone in the treatment of musculoskeletal conditions comprising:</claim-text> providing the patient with a therapeutically effective amount of metaxalone; and informing the patient that the administration of metaxalone with
view more
|
Invalid (102 and 103)
Entry 290 |
2 |
The method according to claim 1, wherein therapeutically effective amount of metaxalone comprises 200 mg to 900 mg of metaxalone.
|
Invalid (102 and 103)
Entry 290 |
3 |
The method according to claim 2, wherein the therapeutically effective amount of metaxalone comprises 400 mg to 800 mg of metaxalone.
|
Invalid (102 and 103)
Entry 290 |
4 |
The method according to claim 1, wherein the metaxalone is provided in tablet form.
|
Invalid (102 and 103)
Entry 290 |
5 |
The method according to claim 4, wherein the tablet is in unit dosage form.
|
Invalid (102 and 103)
Entry 290 |
6 |
A method of using metaxalone in the treatment of musculoskeletal conditions comprising:</claim-text> informing a patient with musculoskeletal conditions that the administration of a therapeutically effective amount of metaxalone with food results in
view more
|
Invalid (102 and 103)
Entry 290 |
7 |
A method of using metaxalone in the treatment of musculoskeletal conditions comprising altering the oral bioavailability of metaxalone by:</claim-text> obtaining metaxalone from a container providing information that administration of metaxalone with
view more
|
Invalid (102 and 103)
Entry 290 |
8 |
A method of using metaxalone in the treatment of musculoskeletal conditions comprising:</claim-text> administering to a patient in need of treatment a therapeutically effective amount of metaxalone, with food, wherein the administration of the
view more
|
Invalid (102 and 103)
Entry 290 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of increasing the oral bioavailability of metaxalone to a patient receiving metaxalone therapy comprising administering to the patient a therapeutically effective amount of metaxalone in a pharmaceutical composition with food.
|
Invalid (102 and 103)
Entry 290 |
2 |
The method of claim 1 wherein the therapeutically effective amount is 200 mg to 900 mg.
|
Invalid (102 and 103)
Entry 290 |
3 |
The method of claim 1 wherein the therapeutically effective amount is 400 mg to 800 mg.
|
Invalid (102 and 103)
Entry 290 |
4 |
The method of claim 1 wherein the administration to the patient occurs between 30 minutes prior to 2 hours after consuming food.
|
Invalid (102 and 103)
Entry 290 |
5 |
The method of claim 1 wherein the administration to the patient is substantially at the same time as the consumption of the food.
|
Invalid (102 and 103)
Entry 290 |
6 |
The method of claim 1 wherein the administration to the patient is immediately after the consumption of food up to 1 hour after said consumption.
|
Invalid (102 and 103)
Entry 290 |
7 |
The method of claim 1 wherein the pharmaceutical composition comprises a tablet.
|
Invalid (102 and 103)
Entry 290 |
8 |
The method of claim 7 wherein the tablet is in unit dosage form.
|
Invalid (102 and 103)
Entry 290 |
9 |
A method of increasing the rate and extent of absorption of an oral dosage form of metaxalone as measured by the drug concentration attained in the blood stream over time in a patient in need of a therapeutic effect thereof comprising, administering
view more
|
Invalid (102 and 103)
Entry 290 |
10 |
The method of claim 9 wherein the therapeutically effective amount is about 200 mg to about 900 mg.
|
Invalid (102 and 103)
Entry 290 |
11 |
The method of claim 9 wherein the therapeutically effective amount is from about 400 mg to about 800 mg.
|
Invalid (102 and 103)
Entry 290 |
12 |
The method of claim 9 wherein the administration to the patient occurs between about 30 minutes prior to about 2 hours after consuming food.
|
Invalid (102 and 103)
Entry 290 |
13 |
The method of claim 9 wherein the administration to the patient is substantially at the same time as the consumption of the food.
|
Invalid (102 and 103)
Entry 290 |
14 |
The method of claim 9 wherein the administration to the patient is immediately after the consumption of food up to about one hour after said consumption.
|
Invalid (102 and 103)
Entry 290 |
15 |
The method of claim 9 wherein the pharmaceutical composition comprises a tablet.
|
Invalid (102 and 103)
Entry 290 |
16 |
The method of claim 15 wherein the pharmaceutical composition comprises a unit dosage form.
|
Invalid (102 and 103)
Entry 290 |
17 |
A method of increasing the oral bioavailability of metaxalone to a patient receiving metaxalone therapy comprising administering to the patient a pharmaceutical tablet comprising 400 mg to 800 mg of metaxalone, with food, wherein the administration
view more
|
Invalid (102 and 103)
Entry 290 |
18 |
The method of claim 17 wherein the administration to the patient occurs between 30 minutes prior to 2 hours after consuming food.
|
Invalid (102 and 103)
Entry 290 |
19 |
The method of claim 17 wherein the administration to the patient is substantially at the same time as the consumption of the food.
|
Invalid (102 and 103)
Entry 290 |
20 |
The method of claim 17 wherein the administration to the patient is immediately after the consumption of food up to 1 hour after said consumption.
|
Invalid (102 and 103)
Entry 290 |
21 |
The method of claim 1, further comprising informing the patient that the administration of a therapeutically effective amount of metaxalone in a pharmaceutical composition with food results in an increase in the maximal plasma concentration (Cmax)
view more
|
Invalid (102 and 103)
Entry 290 |
22 |
The method of claim 1, wherein the metaxalone is from a container with printed labeling advising that administration with food results in an increase in the maximal plasma concentration (Cmax) and extent of absorption (AUC(last)) of metaxalone
view more
|
Invalid (102 and 103)
Entry 290 |